NASDAQ:CTCX Carmell (CTCX) Stock Price, News & Analysis → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free CTCX Stock Alerts $2.53 -0.04 (-1.56%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$2.43▼$2.6550-Day Range$1.98▼$2.9052-Week Range$1.70▼$13.31Volume6,645 shsAverage Volume8,387 shsMarket Capitalization$52.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Carmell alerts: Email Address Carmell MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 9 Articles This WeekInsider TradingAcquiring Shares$42,346 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.32 out of 5 starsMedical Sector920th out of 931 stocksSurgical & Medical Instruments Industry100th out of 101 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Carmell.Read more about Carmell's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.23% of the float of Carmell has been sold short.Short Interest Ratio / Days to CoverCarmell has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Carmell has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCarmell does not currently pay a dividend.Dividend GrowthCarmell does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTCX. Previous Next 2.9 News and Social Media Coverage News SentimentCarmell has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Carmell this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carmell insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,346.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 24.22% of the stock of Carmell is held by institutions.Read more about Carmell's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCarmell has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Carmell's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. About Carmell Stock (NASDAQ:CTCX)Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Its microemulsion formulations do not utilize mineral or vegetable oils and are designed to be non-comedogenic. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics for all fields of use. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Read More CTCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTCX Stock News HeadlinesMay 23, 2024 | insidertrades.comRajiv Shukla Purchases 8,680 Shares of Carmell Co. (NASDAQ:CTCX) StockMay 25 at 6:27 PM | finance.yahoo.comCarmell Corporation (CTCX)May 16, 2024 | investorplace.comCTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023May 16, 2024 | investorplace.comCTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024April 11, 2024 | globenewswire.comCarmell Announces Successful Closing of $3.0 Million Private PlacementApril 4, 2024 | globenewswire.comCarmell Announces $3.0 Million Private PlacementMarch 27, 2024 | globenewswire.comCarmell Announces Successful Closing of Axolotl Biologix Sale TransactionMarch 22, 2024 | investing.comCarmell Corporation divests subsidiary to focus on skincareMarch 20, 2024 | globenewswire.comCarmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix SubsidiaryMarch 18, 2024 | globenewswire.comCarmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics FieldFebruary 28, 2024 | morningstar.comCarmell Corp Ordinary Shares - Class AFebruary 26, 2024 | msn.comWhy Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionFebruary 26, 2024 | globenewswire.comCarmell Announces Product Development Completed for G.L.E.E. Launch in March 2024January 6, 2024 | nasdaq.comCarmell Corporation Common Stock (CTCX)December 9, 2023 | morningstar.comCarmell Corp Ordinary Shares - Class A CTCXNovember 29, 2023 | msn.comCarmell CEO buys shares worth over $15.5k - filingNovember 16, 2023 | finance.yahoo.comCarmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of DirectorsSeptember 12, 2023 | finance.yahoo.comMoonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative MedicineSeptember 5, 2023 | finance.yahoo.comCarmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on AestheticsAugust 19, 2023 | seekingalpha.comCTCX Carmell Therapeutics CorporationAugust 9, 2023 | finance.yahoo.comCarmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand IdentityAugust 6, 2023 | ca.finance.yahoo.comCarmell Therapeutics Corporation (CTCX)August 1, 2023 | morningstar.comCarmell Therapeutics Corp Ordinary Shares - Class AJuly 28, 2023 | barrons.comCarmell Therapeutics Corp.July 28, 2023 | msn.comCarmell jumps on deal to merge with Axolotl BiologixSee More Headlines Receive CTCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carmell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/28/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTCX CUSIPN/A CIK1842939 Webwww.carmellrx.com Phone412-894-8248FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,440,000.00 Net MarginsN/A Pretax Margin-401.27% Return on Equity-171.27% Return on Assets-22.94% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book2.36Miscellaneous Outstanding Shares20,800,000Free FloatN/AMarket Cap$52.62 million OptionableNot Optionable Beta0.42 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Rajiv Sarman Shukla (Age 49)Executive Chairman & CEO Dr. Phil Campbell Ph.D.Founder and Chief Scientific OfficerDr. Lee Weiss Ph.D.FounderDr. James Burgess M.D.FounderBryan J. CassadayChief Financial OfficerKey CompetitorsAVITA MedicalNASDAQ:RCELTriSalus Life SciencesNASDAQ:TLSIOrchestra BioMedNASDAQ:OBIOAlpha Tau MedicalNASDAQ:DRTSClearPoint NeuroNASDAQ:CLPTView All CompetitorsInsiders & InstitutionsRajiv ShuklaBought 1,939 shares on 5/24/2024Total: $4,983.23 ($2.57/share)Rajiv ShuklaBought 4,051 shares on 5/22/2024Total: $9,762.91 ($2.41/share)Rajiv ShuklaBought 1,172 shares on 5/20/2024Total: $2,601.84 ($2.22/share)Hubbell Strickland Wealth Management LLCBought 12,548 shares on 4/18/2024Ownership: 0.065%Rajiv ShuklaBought 8,680 shares on 4/4/2024Total: $24,998.40 ($2.88/share)View All Insider TransactionsView All Institutional Transactions CTCX Stock Analysis - Frequently Asked Questions How have CTCX shares performed in 2024? Carmell's stock was trading at $3.81 at the beginning of 2024. Since then, CTCX stock has decreased by 33.6% and is now trading at $2.53. View the best growth stocks for 2024 here. Are investors shorting Carmell? Carmell saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 30,000 shares, an increase of 8.7% from the April 30th total of 27,600 shares. Based on an average daily volume of 10,500 shares, the days-to-cover ratio is currently 2.9 days. Currently, 0.2% of the company's stock are sold short. View Carmell's Short Interest. When is Carmell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our CTCX earnings forecast. Who are Carmell's major shareholders? Carmell's stock is owned by a number of institutional and retail investors. Top institutional investors include Hubbell Strickland Wealth Management LLC (0.07%). Insiders that own company stock include Bryan J Cassaday, Gilles Spenlehauer, Rajiv Shukla, Randolph W Hubbell, Richard A Upton and Scott M Frisch. View institutional ownership trends. How do I buy shares of Carmell? Shares of CTCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTCX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carmell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.